Life Science SPACs: A Forward Look at this Evolving Asset Class

Back Bay Life Science Report

A tartalmat a Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak biztosítja. Az összes podcast-tartalmat, beleértve az epizódokat, grafikákat és podcast-leírásokat, közvetlenül a Back Bay Life Science Advisors, Jonathan P. Gertler, and Peter Bak vagy a podcast platform partnere tölti fel és biztosítja. Ha úgy gondolja, hogy valaki az Ön engedélye nélkül használja fel a szerzői joggal védett művét, kövesse az itt leírt folyamatot https://hu.player.fm/legal.

3+ y ago 25:17

MP3•Epizód kép

Welcome to Episode #2 of The Life Science Report. In this week’s episode Jonathan Gertler, Back Bay’s CEO and Managing Partner, is joined by Gregory Benning and Vasilios Kofitsas of Back Bay’s investment banking team to talk about the market of Special Purpose Acquisition Companies (SPACs).

The feeling surrounding healthcare SPACs right now is almost...giddy. With enormous capital flowing into the biotech sector, SPACs have emerged as one of the hottest financing options. Last year, the market saw $80B in SPAC issuance, which 2021 will far exceed.

We’re still in the beginning of this market shift, but is the SPAC vehicle the right vehicle to fund the strategy of science?

Topics include:

Traditional IPO markets vs. the hot market of SPACs
How COVID affected the SPAC landscape
The delicate balance of near-term data, valuations & due diligence
Cautions, concerns & the importance of use of proceeds
Regulators & litigation risks in biotech
The potential of U.S. SPAC markets for European companies

Thank you for joining us. To learn more about Back Bay Life Science Advisors, visit our website at www.bblsa.com or follow us on LinkedIn and Twitter.

28 epizódok

#Fitness #Medicine #Bay Life Science Advisors #Jonathan P. Gertler #Biopharma #Investmentbanking #LifeSciences #Medtech